Ferran Fece de la Cruz

10PUBLICATIONS
81CO-AUTHORS
Molecular targetsLiquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Mar 09, 2026
Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition.

Qingxiang Lin, Alvin A Morales-Giron, Conrad Sander

|Jan 08, 2026
Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators.

Ferran Fece de la Cruz, Andreas Varkaris, Parasvi S Patel

|Jan 18, 2024
Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers.

Douglas A Rubinson, Noritaka Tanaka, Ferran Fece de la Cruz

|Nov 02, 2023
Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations.

Andreas Varkaris, Ferran Fece de la Cruz, Elizabeth E Martin

|Oct 16, 2023
Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma.

Qibiao Wu, Haley Ellis, Giulia Siravegna

|Nov 29, 2019
Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition.

Meagan B Ryan, Ferran Fece de la Cruz, Sarah Phat

Pageof 2

Frequent Collaborators

7 joint publications

Ryan B Corcoran

4 joint publications

Bryanna L Norden

4 joint publications

Dejan Juric

4 joint publications

Brandon Nadres